Analysis of RNA sequencing (RNA-seq) data of 985 tumor samples from 967 patients enrolled in the MASTER program22 and 15 samples of the 12 TFCP2-rearranged cases showed that the latter stood out by extremely high ALK expression (Fig. 2a). This evidence concerns the gene ALK and neoplasm.